ONCAlert | 2017 San Antonio Breast Cancer Symposium

A Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer

John Robertson, MD
Published Online:11:50 AM, Wed March 1, 2017

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.